An interventional study of A group-based lifestyle intervention for individuals with OCD and Medical and lifestyle advice in Obsessive Compulsive Disorder (OCD) and Lifestyle (Sedentary Behavior and Physical Activity), sponsored by Karolinska Institutet. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by Karolinska Institutet · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Obsessive-Compulsive Disorder by Karolinska Institutet — 3 open to participants now, 3 under way, none of them phase 3. Obsessive-Compulsive Disorder · Karolinska Institutet.
Among the 17 studies in Obsessive-Compulsive Disorder by Karolinska Institutet, this one is the 5th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 13 with no phase, and was the 17th registered.
637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.
Browse Obsessive-Compulsive Disorder studies →3 of the 17 studies in Obsessive-Compulsive Disorder by Karolinska Institutet are open now, in 1 country. Recruiting first, the newest first:
Karolinska Institutet · Sites in Sweden
Ages 7–17
Karolinska Institutet · Sites in Sweden
Ages 18+
By country, each count listing its studies:
Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 82 (68%) stop at 75 or younger; 28 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 108 is above the median of 45 across 522 interventional studies indexed under Obsessive-Compulsive Disorder.
Median enrollment 83 across the 15 interventional studies, 125 across the 2 observational. Of the 14 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Karolinska Institutet is the lead sponsor of 1,150 studies on the registry; 276 are open to participants now.
1 of the studies in Obsessive-Compulsive Disorder by Karolinska Institutet that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07206212Karolinska InstitutetA Lifestyle Intervention to Reduce Cardiometabolic Risk Factors in Individuals With Obsessive-compulsive Disorder | 2027-11-01 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Obsessive-Compulsive Disorder by Karolinska Institutet, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall aim of this study is to evaluate the efficacy and cost-effectiveness of a lifestyle intervention to improve lifestyle habits and reduce cardiometabolic risk factors in individuals with obsessive-compulsive disorder (OCD).
Obsessive-compulsive disorder (OCD) is a prevalent and impairing disorder with an increased risk of morbidity and mortality due to cardiometabolic diseases. These risks remain significant over and above psychiatric comorbidities and shared familial factors, indicating that at least part of this risk could be a consequence of pernicious lifestyle habits (e.g., physical inactivity, unhealthy diet). A lifestyle intervention targeting cardiometabolic risk factors in people with OCD has previously been deemed feasible, acceptable, and safe. However, the efficacy and cost-effectiveness of the intervention need to be investigated. This will be the first RCT to examine the effects of a lifestyle intervention on the health and well-being of people with OCD.
The specific aims are:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The lifestyle intervention (LIFT) consists of one initial individual session to create a personal plan and set up goals for a change of lifestyle habits (week 1) and 12 weekly group sessions (weeks 2 to 13) including both education on lifestyle habits and physical exercise. After week 13, participants get access to a booster module in a digital platform to help them maintain their behavioral changes.
Behavioral: A group-based lifestyle intervention for individuals with OCD
Participants in this arm will receive one individual session where participants will receive feedback based on the baseline evaluation of their clinical characteristics, lifestyle habits, and cardiometabolic risk (week 1). Additionally, participants will receive written educational information on healthy lifestyle habits.
Behavioral: Medical and lifestyle advice
Participants will take part in 13 week program, with one individual session to set up goals for a change of lifestyle habits, based on the baseline evaluation of their clinical characteristics, lifestyle habits, and cardiometabolic risk, and 12 group sessions, consisting of both education on lifestyle habits and physical exercise. Each educational session will focus on a specific topic/lifestyle habit, alternating more informative sessions with sessions discussing how the information can be applied, taking into account specific hinders due to Obsessive-Compulsive Disorder. Between-sessions homework will include, for example, daily registration of physical activity and implementing changes in the lifestyle habits discussed during each session. All homework assignments will be registered in a digital platform. After the 13 weeks of lifestyle intervention, participants will get access to a booster module in the digital platform to help them maintain their behavioral changes.
Also known as: LIFT
One individual session with a clinical psychologist on week 1 of about 1 hour of duration. During this session, participants will receive feedback based on the baseline evaluation of their clinical characteristics, lifestyle habits, and cardiometabolic risk. Participants also receive written educational information on healthy lifestyle habits based on national Swedish guidelines issued by the National Board of Health and Welfare. The recommendations include engaging in regular physical activity, dietary guidelines based on Nordic Nutrition Recommendations, and advice to reduce alcohol consumption and quit tobacco use.
Physical activity: Steps per day
Measured as change in steps/day with an accelerometer. Participants will be asked to wear an accelerometer (activPAL™) 24 hours/day for seven consecutive days at each assessment point. The device is placed on the thigh. Data will be considered valid if wear time is ≥10 hours/day for at least 4 days, including at least one weekend day.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint.
Physical activity: Moderate to vigorous physical activity (MVPA)
MVPA per day operationalised as a walking cadence of \>100 steps/minute.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint.
International Physical Activity Questionnaire, short form (IPAQ-SF)
Self-reported assessment of physical activity (moderately intense activities, vigorously intense activities, walking) and sedentary time during the last 7 days. Responses on each physical activity intensity question will be converted to metabolic equivalent of task (MET) minutes, using the formula from the IPAQ scoring protocol. Both the continuous and categorical scores (high, moderate, and low) will be calculated according to the scoring guidelines. A higher MET score corresponds to higher levels of physical activity.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 3 months after the primary endpoint, 6 months after the primary endpoint, 12 months after the primary endpoint.
15-item Food Frequency Questionnaire (FFQ)
Self-reported assessment of dietary patterns. It consists of 15 items concerning dietary choices, where each item is evaluated as either meeting or not meeting the guidelines set in the Nordic Nutrition Recommendations (NNR). Each met recommendation receives 1 point, resulting in a healthy eating index ranging from 0 to 15 points. Based on this index, dietary patterns are classified as good (9 or more points), average (6-8 points) or poor (5 or fewer points).
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 3 months after the primary endpoint, 6 months after the primary endpoint, 12 months after the primary endpoint.
Alcohol Use Disorder Identification Test for Consumption (AUDIT-C)
Self-reported assessment of alcohol consumption. Scores in the AUDIT-C range from 0 to 12 points, where 0 points indicate no alcohol use. Cut-off scores for risk consumption vary across settings and population, but a score ≥4 points has been suggested as a cut-off for detecting risk consumption of alcohol when validated in the general population.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 3 months after the primary endpoint, 6 months after the primary endpoint, 12 months after the primary endpoint.
Tobacco use
Evaluated by asking self-reported questions about current or previous use of cigarettes, snus or other tobacco or nicotine products. If current use, or if they quit during the last 6 months, participants are asked to specify frequency (daily, sometimes) and amount used.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 3 months after the primary endpoint, 6 months after the primary endpoint, 12 months after the primary endpoint.
Perceived Stress Scale (PSS)
Self-reported assessment of perceived stress. The total score ranges from 0 to 40, with higher scores indicating higher levels of perceived stress.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 3 months after the primary endpoint, 6 months after the primary endpoint, 12 months after the primary endpoint.
Insomnia Severity Scale (ISI)
Self-reported assessment of sleep problems and severity of symptoms. Consists of 7 items that are rated on a 5-point Likert scale to evaluate sleep problems and severity of symptoms. The total score ranges from 0 to 28 points, with a higher score indicating more severe sleep problems.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 3 months after the primary endpoint, 6 months after the primary endpoint, 12 months after the primary endpoint.
Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
Clinician-rated semi-structured interview to assess OCD symptom severity. The Y-BOCS consists of 10 items rated from 0 to 4, with a total score from 0 to 40, where a higher score corresponds to more severe OCD.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 3 months after the primary endpoint, 6 months after the primary endpoint, 12 months after the primary endpoint.
Obsessive-Compulsive Inventory - 12 (OCI-12)
Self-reported assessment of OCD symptoms. Consists of 12 items rated on a 5-point Likert scale, with total scores ranging from 0-48. Scores between 0 and 12 indicate mild, between 13 and 21 indicate moderate, and between 22 and 48 indicate severe OCD symptoms.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 3 months after the primary endpoint, 6 months after the primary endpoint, 12 months after the primary endpoint.
Patient Health Questionnaire (PHQ-9)
Self-reported assessment of symptoms of depression. In this 9-item scale the total score ranges from 0 to 27 points, with a higher score corresponding to more severe symptoms of depression.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 3 months after the primary endpoint, 6 months after the primary endpoint, 12 months after the primary endpoint.
EuroQol five dimensional five level questionnaire (EQ-5D-5L)
Self-rated assessment of own health status in five dimensions (mobility; self-care; usual activities; pain/discomfort; and anxiety/depression), within five levels of severity (no problems; slight problems; moderate problems; severe problems; or extreme problems). The scale also comprises a rating of their overall health status on a scale from 0-100 (0 = worst imaginable health; 100 = best imaginable health), the EQ-VAS scale. The scores are combined to calculate a health utility number, with the health utilities ranging from -0.31 for the worst to 1 for the best EQ-5D-5L states in Sweden.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 3 months after the primary endpoint, 6 months after the primary endpoint, 12 months after the primary endpoint.
Work and Social Adjustment Scale (WSAS)
Self-reported assessment of impairment in functioning, in terms of work, home management, social leisure activities, private leisure activities, and relationships. Each item is rated on a scale from 0 to 8, with the total score ranging from 0 to 40. A higher score corresponds to more impairment in functioning.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 3 months after the primary endpoint, 6 months after the primary endpoint, 12 months after the primary endpoint.
Waist circumference
Measured in a standing position, midway between the lower rib margin and the iliac crest, in centimeters (cm) at the nearest 0.5 cm.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint.
Sagittal abdominal diameter
Measured in a supine position at the nearest 0.1 centimeter with a ruler and a water lever or a caliper, at the level of the umbilical.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint.
Weight
Measured in kilograms, to the nearest 0.1 kg.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint.
Body Mass Index (BMI)
Derived by dividing weight (in kilograms measured to the nearest 0.1 kg) by height (in meters measured to the nearest 0.1 cm) squared.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint.
Systolic and diastolic blood pressure
Measured in a seated position after ten minutes of rest, with a standard sphygmomanometer. The measurement will be taken twice with 1 minute between measures, according to the gold standard for measuring blood pressure.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint.
Resting heart rate
Measured in a seated position following a 5 minute rest.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint.
Total cholesterol
Blood will be drawn following an overnight fast (minimum 8 hours, or else rescheduled). Measured as mmol/l.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint.
S-low density lipoprotein cholesterol
Blood will be drawn following an overnight fast (minimum 8 hours, or else rescheduled). Measured as mmol/l.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint.
S-high density lipoprotein cholesterol
Blood will be drawn following an overnight fast (minimum 8 hours, or else rescheduled). Measured as mmol/l.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint.
Lipoprotein (a)
Blood will be drawn following an overnight fast (minimum 8 hours, or else rescheduled). Measured as nmol/l.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint.
Fasting triglycerides
Blood will be drawn following an overnight fast (minimum 8 hours). Measured as mmol/l.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint.
Fasting plasma glucose
Blood will be drawn following an overnight fast (minimum 8 hours). Measured as mmol/l.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint.
Glycated hemoglobin
Blood will be drawn following an overnight fast (minimum 8 hours) (HbA1c, mmol/l). It reflects average plasma glucose over the previous 8-12 weeks.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint.
Thyroid stimulating hormone (TSH)
Blood will be drawn following an overnight fast (minimum 8 hours). Measured as mE/L.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint.
Cobalamin
Blood will be drawn following an overnight fast (minimum 8 hours). Reflects vitamin B12 status. Measured in pmol/L.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint.
Homocysteine
Blood will be drawn following an overnight fast (minimum 8 hours). Measured in µmol/L.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint.
25-OHD-vitamin
Blood will be drawn following an overnight fast (minimum 8 hours). Main marker of vitamin D status in the body, reported in nmol/L.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint.
Folate
Blood will be drawn following an overnight fast (minimum 8 hours). Reported in nmol/L.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint.
Iron deposits: Iron
Blood will be drawn following an overnight fast (minimum 8 hours). Iron \[Fe\], reported in µmol/L.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint.
Iron deposits: Transferrin
Blood will be drawn following an overnight fast (minimum 8 hours). Reported in µg/L.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint.
High-sensitive C-reactive protein (CRP)
Blood will be drawn following an overnight fast (minimum 8 hours). Reported in mg/L.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint.
White blood cell telomere length
Blood will be drawn following an overnight fast (minimum 8 hours). Telomere length in leukocytes will be measured, reported as relative telomere length (T/S ratio).
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint).
Inflammation panel
Blood will be drawn following an overnight fast (minimum 8 hours). Immune activity plasma proteins (n=92) will be analysed using the Olink Target 96 Inflammation panel.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint).
Extracellular vesicles (EVs)
Blood will be drawn following an overnight fast (minimum 8 hours). EVs will be isolated from plasma using differential ultracentrifugation. Quantification and separation of EVs will be performed using flow cytometry using antibodies specifically marking EVs with regards to being a microparticle and their tissue of origin. We will investigate the amount and origin of EVs from the vascular endothelium, leukocytes, platelets, and the skeletal muscle. To assess the cargo of particularly interesting EVs, RNA will be isolated and miRNA profiled using the robust and high-throughput nCounter (Nanostring).
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint).
Biological age
Blood will be drawn following an overnight fast (minimum 8 hours). DNA will be extracted using the Chemagen kits on the Hamilton ChemagicSTAR® platform. Bisulfite conversion will be conducted using the EZ-96 DNA Methylation-Lightning Kit (D5033). The Illumina Infinium MethylationEPIC v.2 array will be used to quantify DNAm at \~930,000 sites. Raw methylation data will be pre-processed using standard quality control steps, including removal of low-quality probes (e.g., detection p-value \>0.01), background correction, and normalization. Biological aging patterns will be assessed through epigenetic age calculations using state-of-the-art algorithms (e.g., GrimAge). Accelerated biological age will be calculated as the residual from regressing epigenetic age on chronological age.
Time frame: Baseline, week 14 after the start of the intervention (primary endpoint).
Adverse events
Measured with a short questionnaire created by the research team regarding potential adverse events (e.g., increased anxiety, headaches, increased tiredness, musculoskeletal pain). They will also be able to write own examples on negative experiences connected to participation in the intervention.
Time frame: Week 7 after the start of the intervention, week 14 after the start of the intervention (primary endpoint).
Concurrent interventions
At each measurement point, information will be collected on any treatment changes (e.g., changes in medication, initiation of psychological treatment) and/or initiation of concurrent interventions to improve lifestyle habits (including e.g., vitamin supplements) or cardiometabolic risk factors.
Time frame: Baseline, week 7 after the start of the intervention, week 14 after the start of the intervention (primary endpoint), 3 months after the primary endpoint, 6 months after the primary endpoint, 12 months after the primary endpoint.
Plan to share: No — The investigators may potentially share trial data from the study with other researchers around the world. The use would primarily be to combine outcome data for potential meta-analyses in this research field. Shared data will be pseudonymised. The possibility of future data sharing is mentioned in the informed consent form.
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Nov 2027, 21 months after the start.
Of 235 non-industry interventional studies with no phase under Obsessive-Compulsive Disorder, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 63. This study's planned 21 months is below that.
Counting every sponsor, half of 238 studies reached it within 43 months; a quarter within 22 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Obsessive-Compulsive Disorder →